Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer

I Cohen, Ilan Cohen, Doron J.D. Rosen, D J Rosen, Jeremiah Shapira, J Shapira, Mario Cordoba, M Cordoba, Shlomo Gilboa, S Gilboa, Marco M. Altaras, M M Altaras, D Yigael, Dror Yigael, Y Beyth, Yoram Beyth
British journal of obstetrics and gynaecology · 1993 · vol. 100(6) , pp. 567–570 · doi:10.1111/j.1471-0528.1993.tb15310.x · PMID:8334093 · W1971823947
Observational OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This cross-sectional study found no predictive risk factors for endometrial pathologies in asymptomatic postmenopausal breast cancer patients treated with tamoxifen, suggesting routine endometrial sampling is necessary.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To evaluate whether risk factors, other than tamoxifen, can be identified for the development of endometrial pathologies in postmenopausal breast cancer patients treated with tamoxifen. DESIGN: A cross-sectional study. SETTING: Department of Obstetrics and Gynaecology and Oncology Clinic, Sapir Medical Center, Kfar Saba, Israel. SUBJECTS: 77 asymptomatic postmenopausal women, treated with tamoxifen for breast cancer. Of these, 55 had no endometrial tissue and 22 had endometrial tissue obtained by biopsy. MAIN OUTCOME MEASURES: Demographic characteristics, health habits, risk factors, vaginal ultrasonographic evaluations of endometrial thickness and texture, and histologic evaluations of endometrial biopsies. RESULTS: Overall, there was a high rate (29%) of endometrial pathological change among the 77 asymptomatic postmenopausal women. There were no significant statistical differences in the features tested between the two groups. CONCLUSION: It is impossible to predict which postmenopausal women will develop pathological endometrial changes after treatment with tamoxifen and thus a routine periodic endometrial sampling-follow up is suggested for all postmenopausal women being treated with this agent.

My notes (saved in your browser only)

MeSH descriptors

Breast Neoplasms Endometrium Tamoxifen Uterine Neoplasms Aged Breast Neoplasms Breast Neoplasms Cross-Sectional Studies Endometrium Endometrium Female Humans Menopause Middle Aged Polyps Polyps Polyps Tamoxifen Tamoxifen Uterine Neoplasms

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (22)

Cited by (6)

Source provenance

openalex
last seen: 2026-05-14T06:03:08.038466+00:00
pubmed
last seen: 2026-10-08T21:59:31.578486+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00
License: CC0 · commercial use OK